Rubius Therapeutics Inc (NASDAQ:RUBY) Director Robert Langer sold 7,500 shares of the company’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $14.94, for a total value of $112,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
NASDAQ RUBY opened at $14.93 on Friday. The stock has a market cap of $1.18 billion and a PE ratio of -6.58. The company has a current ratio of 18.64, a quick ratio of 18.64 and a debt-to-equity ratio of 0.13. Rubius Therapeutics Inc has a twelve month low of $12.70 and a twelve month high of $27.73. The business’s fifty day simple moving average is $14.67.
Rubius Therapeutics (NASDAQ:RUBY) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). Analysts expect that Rubius Therapeutics Inc will post -1.84 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jennison Associates LLC grew its holdings in shares of Rubius Therapeutics by 0.4% during the 1st quarter. Jennison Associates LLC now owns 479,398 shares of the company’s stock worth $8,677,000 after purchasing an additional 1,802 shares during the period. Metropolitan Life Insurance Co NY grew its holdings in shares of Rubius Therapeutics by 65.0% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 11,867 shares of the company’s stock worth $214,000 after purchasing an additional 4,676 shares during the period. Metropolitan Life Insurance Co. NY grew its holdings in shares of Rubius Therapeutics by 320.5% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,191 shares of the company’s stock worth $116,000 after purchasing an additional 5,481 shares during the period. MetLife Investment Advisors LLC grew its holdings in shares of Rubius Therapeutics by 52.2% during the 1st quarter. MetLife Investment Advisors LLC now owns 16,410 shares of the company’s stock worth $297,000 after purchasing an additional 5,629 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of Rubius Therapeutics during the 1st quarter worth $117,000. Institutional investors and hedge funds own 93.75% of the company’s stock.
About Rubius Therapeutics
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.
Featured Story: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.